Trials / Unknown
UnknownNCT03390062
A Study of Apatinib in Recurrent or Recurrent High-grade Glioma
An One Arm, Open and Prospective Studyof Apatinib for the Treatment of Recurrent or Recurrent High-grade Glioma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- West China Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness and safety of Apatinib for patients with Recurrent or Recurrent High-grade Glioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. |
Timeline
- Start date
- 2018-01-04
- Primary completion
- 2019-12-20
- Completion
- 2020-08-01
- First posted
- 2018-01-04
- Last updated
- 2018-01-04
Source: ClinicalTrials.gov record NCT03390062. Inclusion in this directory is not an endorsement.